ES2483116A2 - Compuestos útiles para el tratamiento de infecciones bacterianas, composiciones farmacéuticas que los contienen, procedimiento de identificación de los mismos y sus aplicaciones - Google Patents

Compuestos útiles para el tratamiento de infecciones bacterianas, composiciones farmacéuticas que los contienen, procedimiento de identificación de los mismos y sus aplicaciones Download PDF

Info

Publication number
ES2483116A2
ES2483116A2 ES201232017A ES201232017A ES2483116A2 ES 2483116 A2 ES2483116 A2 ES 2483116A2 ES 201232017 A ES201232017 A ES 201232017A ES 201232017 A ES201232017 A ES 201232017A ES 2483116 A2 ES2483116 A2 ES 2483116A2
Authority
ES
Spain
Prior art keywords
compounds
treatment
pharmaceutical compositions
bacterial
bacterial infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201232017A
Other languages
English (en)
Other versions
ES2483116B1 (es
ES2483116R1 (es
Inventor
Javier Pozueta Romero
Edurne BAROJA FERNÁNDEZ
Francisco José Muñoz Pérez
Mehdi RAHIMPOUR
Manuel Montero Macarro
Goizeder ALMAGRO ZABALZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Publica de Navarra
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad Publica de Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad Publica de Navarra filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201232017A priority Critical patent/ES2483116B1/es
Priority to PCT/ES2013/070925 priority patent/WO2014102432A1/es
Publication of ES2483116A2 publication Critical patent/ES2483116A2/es
Publication of ES2483116R1 publication Critical patent/ES2483116R1/es
Application granted granted Critical
Publication of ES2483116B1 publication Critical patent/ES2483116B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07027—Glucose-1-phosphate adenylyltransferase (2.7.7.27), i.e. ADP-glucose pyrophosphorylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención describe una serie de compuestos útiles para reducir o anular procesos determinantes de la patogenicidad y virulencia bacterianas y de la adherencia bacteriana a superficies inertes o células tales como la producción de adhesinas, la motilidad flagelar y la formación de EPSs y biofilms bacterianos. Estos compuestos pueden usarse para la elaboración de composiciones farmacéuticas antibacterianas o de composiciones antisépticas para el tratamiento de un amplio abanico de infecciones bacterianas, como por ejemplo, E. coli, S. typhi, S. dysenteteriae, V. chlolerae, P. aeruginosa, H. pylori, L. monocytogenes, C. difficile y S. pyogenes. Además, se describe un procedimiento para la identificación de dichos compuestos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22

Claims (1)

  1. imagen1
    imagen2
ES201232017A 2012-12-24 2012-12-24 Compuestos útiles para el tratamiento de infecciones bacterianas, composiciones farmacéuticas que los contienen, procedimiento de identificación de los mismos y sus aplicaciones Withdrawn - After Issue ES2483116B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201232017A ES2483116B1 (es) 2012-12-24 2012-12-24 Compuestos útiles para el tratamiento de infecciones bacterianas, composiciones farmacéuticas que los contienen, procedimiento de identificación de los mismos y sus aplicaciones
PCT/ES2013/070925 WO2014102432A1 (es) 2012-12-24 2013-12-24 Compuestos útiles para el tratamiento de infecciones bacterianas, composiciones farmacéuticas que los contienen, procedimiento de identificación de los mismos y sus aplicaciones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201232017A ES2483116B1 (es) 2012-12-24 2012-12-24 Compuestos útiles para el tratamiento de infecciones bacterianas, composiciones farmacéuticas que los contienen, procedimiento de identificación de los mismos y sus aplicaciones

Publications (3)

Publication Number Publication Date
ES2483116A2 true ES2483116A2 (es) 2014-08-05
ES2483116R1 ES2483116R1 (es) 2014-10-21
ES2483116B1 ES2483116B1 (es) 2015-09-10

Family

ID=51019935

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201232017A Withdrawn - After Issue ES2483116B1 (es) 2012-12-24 2012-12-24 Compuestos útiles para el tratamiento de infecciones bacterianas, composiciones farmacéuticas que los contienen, procedimiento de identificación de los mismos y sus aplicaciones

Country Status (2)

Country Link
ES (1) ES2483116B1 (es)
WO (1) WO2014102432A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220287995A1 (en) * 2019-07-30 2022-09-15 The Regents Of The University Of California Compositions and methods for inhibiting bacterial virulence and flim-based device and method for antibiotic susceptibility testing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134640A1 (en) * 2003-04-22 2006-06-22 Institut Pasteur Inhibiting the growth of bacterial biofilms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134640A1 (en) * 2003-04-22 2006-06-22 Institut Pasteur Inhibiting the growth of bacterial biofilms

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BALLICORA M A et al. ADP-glucose pyrophosphorylase, a regulatory enzyme for bacterial glycogen synthesis.Microbiology and Molecular Biology Reviews 200306 us 00/06/2003 VOL: 67 No: 2 Pags: 213 - 225 ISSN 1092-2172 (print) Doi: doi:10.1128/MMBR.67.2.213-225.2003BALLICORA M A et al. ADP-glucose pyrophosphorylase, a regulatory enzyme for bacterial glycogen synthesis.Microbiology and Molecular Biology Reviews 200306 us 00/06/2003 VOL: 67 No: 2 Pags: 213 - 225 ISSN 1092-2172 (print) Doi: doi:10.1128/MMBR.67.2.213-225.2003 *
Base de datos EMBL-EBI. ¿Online¿. (16-08-2012).¿Proteins and nucleic acids from meningitis/sepsis-associated escherichia col¿. JP-2012116975-A (NOVARTISVACCINES). Databaseaccession no. HW283808.Esta secuencia muestra un 99.7% de identidad con SEQ. ID. Nº 1 en un solapamiento de 1296 nt.Base de datos EMBL-EBI. ¿Online¿. (16-08-2012).¿Proteins and nucleic acids from meningitis/sepsis-associated escherichia col¿. JP-2012116975-A (NOVARTISVACCINES). Databaseaccession no. HW283808.Esta secuencia muestra un 99.7% de identidad con SEQ. ID. Nº 1 en un solapamiento de 1296 nt. *
Base de datos EMBL-EBI. ¿Online¿.(27-03-2008).(METANOMICSGMBH). Sequence 31234 from PatentWO2008034648.Database accession no. FB811961. Esta secuencia muestra un 100% de identidad con SEQ. ID. Nº5 en un solapamiento de 1563nt. *
Base de datos EMBL-EBI.¿Online¿. (09-07-2007).AJINOMOTO KK. WO2006078050A2 (27.07.2006). Sequence19 from Patent WO2006078050. Database accession no. CS682295. Esta secuencia muestra un 100%de indentidad con SEQ. ID. Nº 3 en un solapamiento de 201 nt. *
Base de datos UniProt-EMBL-EBI. ¿Online¿. (01-10-1996).¿Glucose-1-phosphate adenylyltransferase smallsubunit, chloroplastic Arabidopsis ¿. Database accession no. GLGS_ARATH. Esta secuencia muestra un 100%de indentidad con SEQ. ID. Nº 6 en un solapamiento de 520 aa. *
Base de datos UniProt-EMBL-EBI. ¿Online¿. (05-09-2012).¿Glycogen synthesis protein GlgS Escherichiacoli". Database accessionno. I6FYR8_ECOLX. Esta secuencia muestra un 100% de identidad con SEQ. ID. Nº 4 en un solapamiento de 66 aa. *
Base de datos UniProt-EMBL-EBI. ¿Online¿.(28- 12012).¿Glucose1phosphateadenylyltransferase Escherichia coli ¿. Database accession no. K3RGT0_ECOLX. Esta secuencia muestra un 100% de identidad con SEQ. ID. Nº 2 en un solapamiento de 431 aa. *
EYDALLIN G et al. Genome-wide screening of genes whose enhanced expression affects glycogen accumulation in escherichia coli.DNA Research 2010 Oxford University Press gbr 00/04/2010 VOL: 17 No: 2 Pags: 61 - 71 ISSN 1340-2838 (print) ISSN 1756-1663 (electronic) Doi: doi:10.1093/dnares/dsp028 *

Also Published As

Publication number Publication date
ES2483116B1 (es) 2015-09-10
WO2014102432A1 (es) 2014-07-03
ES2483116R1 (es) 2014-10-21

Similar Documents

Publication Publication Date Title
WO2018156916A3 (en) Pharmaceutical compositions of a bile acid derivative and microbiome and uses thereof
EA201792548A1 (ru) 4-гидрокси-3-(гетероарил)пиридин-2-оновые агонисты apj для применения в лечении сердечно-сосудистых заболеваний
MX2017014035A (es) Formas solidas novedosas.
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
EA201890771A1 (ru) Соли и твердые формы монобактамного антибиотика
EP4268897A3 (en) Minocycline compounds for biodefense
UA111210C2 (uk) Антибактеріальні 3,4-дигідро-1h-[1,8]нафтиридинони, заміщені циклопента[c]піролом
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
WO2017218922A3 (en) Compositions and methods for the treatment of bacterial infections
BR112016017776A8 (pt) forma cristalina ou forma sólida de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidróxi-4-metil-ciclo-hexilamino)-pirimidina-5-carboxamida, método de preparo, método de purificação, composto, composição farmacêutica e uso de forma cristalina ou forma sólida
PH12016500461A1 (en) Polyethylene glycol-containing composition
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
WO2016142819A3 (en) Novel process for the preparation of ranolazine
WO2015114452A3 (en) Antibacterial combinations comprising polymyxin
PH12016502568A1 (en) Novel heterocyclic compound
EA201791670A1 (ru) Твердые композиции для ухода за полостью рта
ES2483116A2 (es) Compuestos útiles para el tratamiento de infecciones bacterianas, composiciones farmacéuticas que los contienen, procedimiento de identificación de los mismos y sus aplicaciones
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
WO2019101937A3 (en) Inhibitors of the shikimate pathway and use of 7-deoxy-sedoheptulose as antimicrobial and herbicidal agent
WO2017093543A3 (en) Thiol phosphine gold complexes for use in treating bacterial infections
WO2016073493A3 (en) Antifibrinolytic compounds
PL414935A1 (pl) Sposób otrzymywania 6-acetamidoflawonu
MY180113A (en) Use of patchouli extract in the preparation of compositions with an anti-microorganism effect
WO2017140683A3 (en) Streptococcus uberis extract as an immunogenic agent
EA201791653A1 (ru) Твердые композиции для ухода за полостью рта

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2483116

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150910

FA2A Application withdrawn

Effective date: 20160204